Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (KRRO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -19,625 | -50,042 | -18,061 | -49,157 |
| Non-cash lease expense | 242 | 226 | 178 | 326 |
| Stock-based compensation expense | 2,731 | 2,071 | 1,825 | 3,759 |
| Depreciation expense | 380 | 649 | 1,179 | 2,452 |
| Long-lived asset impairment charge | NaN | 30,886 | NaN | NaN |
| Net amortization of premiums and discounts on marketable securities | -2 | 22 | 467 | NaN |
| Loss on disposal of property and equipment | NaN | 18 | -81 | NaN |
| Accounts receivable | -969 | 149 | -876 | NaN |
| Prepaid expenses and other current assets | -54 | 1,485 | 189 | NaN |
| Accounts payable | -153 | -637 | -1,674 | NaN |
| Accrued expenses and other current liabilities | -205 | 1,750 | -319 | NaN |
| Deferred revenue | 0 | -322 | -1,268 | NaN |
| Operating lease liabilities | -601 | -1,182 | -97 | NaN |
| Other non-current assets | -132 | -573 | 303 | NaN |
| Net cash used in operating activities | -16,074 | -17,702 | -17,179 | -43,680 |
| Purchases of marketable securities | 45,219 | 0 | 15,028 | 11,161 |
| Proceeds from maturities of marketable securities | 13,000 | 15,000 | 22,799 | 32,901 |
| Purchases of property and equipment | 21 | 84 | 175 | 259 |
| Net cash provided by (used in) investing activities | -32,240 | 14,916 | 7,596 | 21,481 |
| Proceeds from the issuance of common stock in connection with the at-the-market program, net of offering costs | 5,041 | 0 | 0 | 0 |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with the private placement, net of offering costs | 83,154 | NaN | NaN | NaN |
| Proceeds from exercises of stock options | 17 | 380 | 128 | 177 |
| Net cash provided by financing activities | 88,212 | 380 | 128 | 177 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -25 | 75 | -2 | -9 |
| Net decrease in cash, cash equivalents and restricted cash | 39,873 | -2,331 | -9,457 | -22,031 |
| Cash, cash equivalents and restricted cash, beginning of period | 25,230 | 27,561 | 59,049 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 65,103 | 25,230 | 27,561 | NaN |